Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “MEK Mutation”

74 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 74 results

Early research (Phase 1)Study completedNCT04967079
What this trial is testing

Trametinib Plus Anlotinib in Non-G12C KRAS-Mutant NSCLC Patients

Who this might be right for
Non Small Cell Lung Cancer
Shanghai Chest Hospital 33
Large-scale testing (Phase 3)Study completedNCT01245062
What this trial is testing

GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma

Who this might be right for
Melanoma
GlaxoSmithKline 322
Early research (Phase 1)Looking for participantsNCT04903119
What this trial is testing

Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma

Who this might be right for
Metastatic MelanomaBRAF Gene Mutation
Rina Plattner 30
Testing effectiveness (Phase 2)Ended earlyNCT02314143
What this trial is testing

Phase II Biomarker Study Comparing the Combination of BRAF Inhibitor Dabrafenib With MEK Inhibitor Trametinib Versus the Combination After Monotherapy With Dabrafenib or Trametinib

Who this might be right for
Melanoma
GlaxoSmithKline 48
Not applicableLooking for participantsNCT05630989
What this trial is testing

A Registry to Capture Patient Outcomes With KRAS G12R Altered Advanced Pancreatic Ductal Adenocarcinoma Treated With MEK Inhibitor-based Combination Therapy

Who this might be right for
Pancreatic Ductal Adenocarcinoma
Mandana Kamgar, MD 80
Testing effectiveness (Phase 2)Study completedNCT01362296
What this trial is testing

An Open-label Study of GSK1120212 Compared With Docetaxel in Stage IV KRAS-mutant Non-small Cell Lung Cancer

Who this might be right for
Lung Cancer, Non-Small Cell
GlaxoSmithKline 134
Early research (Phase 1)Looking for participantsNCT06299839
What this trial is testing

PAS-004 in Patients With Advanced Solid Tumors

Who this might be right for
RAS MutationNF1 MutationRAF Mutation+1 more
Pasithea Therapeutics Corp. 48
Testing effectiveness (Phase 2)Ended earlyNCT01907815
What this trial is testing

Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Acute Myeloid Leukemia

Who this might be right for
Recurrent Adult Acute Myeloid LeukemiaUntreated Adult Acute Myeloid Leukemia
National Cancer Institute (NCI) 24
Not applicableStudy completedNCT03416933
What this trial is testing

Therapeutic Drug Monitoring of BRAF-mutated Advanced Melanoma

Who this might be right for
Melanoma (Skin)
Institut de Cancérologie de Lorraine 35
Testing effectiveness (Phase 2)WithdrawnNCT03109301
What this trial is testing

Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in People With Neurofibromatosis Type 1 (NF1) Mutated Gastrointestinal Stromal Tumors (GIST)

Who this might be right for
Neoplasms, Nerve TissueNeurofibromatosis 1Heredodegenerative Disorders, Nervous System+1 more
National Cancer Institute (NCI)
Testing effectiveness (Phase 2)Study completedNCT02448290
What this trial is testing

Single-arm Study of Selumetinib in Combination With Docetaxel, in Advanced Gastric Adenocarcinoma Patients With Low/High MEK Signature, RAS Mutation or RAS Amplification as a Second-line Chemotherapy

Who this might be right for
Gastric Adenocarcinoma
Samsung Medical Center 25
Early research (Phase 1)Study completedNCT01337765
What this trial is testing

Safety, Pharmacokinetics and Pharmacodynamics of BEZ235 Plus MEK162 in Selected Advanced Solid Tumor Patients

Who this might be right for
Unspecified Adult Solid Tumor, Protocol SpecificSolid Tumor
Pfizer 29
Testing effectiveness (Phase 2)Study completedNCT00866177
What this trial is testing

MEK Inhibitor AZD6244 in Treating Patients With Stage III or Stage IV Melanoma

Who this might be right for
Recurrent MelanomaStage III Skin MelanomaStage IV Skin Melanoma
National Cancer Institute (NCI) 167
Early research (Phase 1)Ended earlyNCT01940809
What this trial is testing

Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery

Who this might be right for
BRAF V600E Mutation PresentBRAF V600K Mutation PresentMetastatic Melanoma+5 more
National Cancer Institute (NCI) 15
Testing effectiveness (Phase 2)Active Not RecruitingNCT02079740
What this trial is testing

Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors

Who this might be right for
Metastatic Malignant Solid NeoplasmRefractory Malignant Solid NeoplasmUnresectable Malignant Solid Neoplasm
National Cancer Institute (NCI) 96
Testing effectiveness (Phase 2)Study completedNCT02296112
What this trial is testing

Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations

Who this might be right for
Recurrent MelanomaStage IIIB MelanomaStage IIIC Melanoma+1 more
Vanderbilt-Ingram Cancer Center 9
Testing effectiveness (Phase 2)Study completedNCT01693068
What this trial is testing

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Who this might be right for
N-Ras Mutated Locally Advanced or Metastasis Malignant Cutaneous Melanoma
EMD Serono 194
Testing effectiveness (Phase 2)Study completedNCT01037127
What this trial is testing

Study to Determine the Effectiveness of GSK1120212 in BRAF Mutation-positive Melanoma Previously Treated With or Without a BRAF Inhibitor

Who this might be right for
Cancer
GlaxoSmithKline 97
Testing effectiveness (Phase 2)Active Not RecruitingNCT04625270
What this trial is testing

Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation

Who this might be right for
Low Grade Ovarian Serous AdenocarcinomaOvarian Cancer
Verastem, Inc. 225
Early research (Phase 1)Temporarily pausedNCT03932253
What this trial is testing

MEK Inhibitor FCN-159 To Treat Advanced Melanoma With NRAS-aberrant (Ia) and NRAS-mutant (Ib)or NF1-mutant(1b)

Who this might be right for
Melanoma
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. 79
Next Page